GPs air criticism of NICE RA advice

NICE has approved rituximab in combination with methotrexate for RA patients responding inadequately to anti-TNF therapy in draft guidance.

But it has rejected the routine use of the TNF inhibitors adalimumab, etanercept and infliximab after failure of another anti-TNF - such treatment should be limited to research studies, it said. NICE also rejected use of abatacept after failure of a TNF inhibitor.

Greater Manchester GP Dr Adam Bajkowski, a Primary Care Rheumatology Society member, said NICE needed to remember its role was to offer guidance.

'Informing one's colleagues that the current evidence would support first-line usage of rituximab over other biologicals after previous failures, is a far better way to communicate findings than simply stating rituximab is what you have to use, full stop.'

Dr Louise Warburton, a GPSI in rheumatology and musculoskeletal medicine in Shropshire, said: 'It is a shame NICE won't allow a second anti-TNF. The lack of evidence is a measure of the fact that the research has not yet been done, not a measure of ineffectiveness.'

The draft recommendations are open for consultation on the NICE website until 24 March.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus